Modeling HSV-1 Latency in Human Sensory Neurons Using hiPSC Technology

Study Background and Research Question

Herpes simplex virus 1 (HSV-1) is a widespread human pathogen responsible for a spectrum of diseases, from common mucocutaneous lesions to severe neurological complications such as keratitis and encephalitis. Despite the clinical burden, much of our understanding of HSV-1 latency and reactivation mechanisms has been derived from animal models, which may not fully recapitulate the complexities of human neuronal biology. The major challenge has been the lack of scalable, physiologically relevant in vitro systems of human sensory neurons capable of supporting latent HSV-1 infection. This gap has hindered mechanistic studies and the development of strategies to prevent viral reactivation.

Key Innovation from the Reference Study

In their recent publication (Oh et al., 2025), the authors present a novel and robust protocol for rapidly differentiating human inducible pluripotent stem cells (hiPSCs) into mature, functional sensory neurons. These neurons exhibit appropriate electrophysiological properties and express sensory neuron-specific ion channels. Critically, the study demonstrates that these hiPSC-derived sensory neurons serve as a scalable human model system that supports HSV-1 latency and reactivation in vitro, fulfilling key criteria for physiological relevance and experimental flexibility.

Methods and Experimental Design Insights

The research team established a stepwise protocol for differentiating hiPSCs into sensory neurons, verifying the neuronal identity and functional maturity of the resulting cells through a combination of transcriptomic, immunocytochemical, and electrophysiological assessments. The neurons were then subjected to infection with HSV-1 under conditions designed to promote latent infection, monitored for hallmark features such as the absence of infectious virus production, suppression of lytic gene expression, and abundant latency-associated transcript (LAT) expression. Chromatin immunoprecipitation (ChIP) assays were employed to assess the epigenetic landscape of the HSV-1 genome within these neurons, with a focus on heterochromatin markers that characterize latency. To probe reactivation, the model utilized established stimuli (forskolin, PI3K inhibitors) to induce a switch from latency to lytic viral gene expression and viral production.

Protocol Parameters

• hiPSC differentiation: Sequential application of growth factors and small molecules to induce sensory neuron fate, typically over 3-4 weeks.
• Neuronal maturation validation: Electrophysiological assays to confirm action potential firing and ion channel expression.
• HSV-1 infection for latency: Application of HSV-1 at a multiplicity of infection (MOI) optimized to minimize cytopathic effects, followed by maintenance in latency-permissive medium.
• Latency confirmation: Quantification of LAT expression, monitoring for absence of infectious virus, and ChIP for heterochromatin marks (H3K9me3, H3K27me3) on the viral genome.
• Reactivation assay: Application of forskolin or PI3K inhibitors to trigger viral lytic cycle entry and production of infectious virus.
• Downstream signaling analysis: Immunoblot or immunocytochemistry for phosphorylated ERK1/2 and STAT3 (optional, for pathway interrogation).

Core Findings and Why They Matter

The study validated that hiPSC-derived sensory neurons can support all key features of HSV-1 latency observed in vivo: (1) lack of infectious virus production, (2) suppression of lytic gene expression, (3) robust expression of the latency-associated transcript, and (4) establishment of facultative heterochromatin on the viral genome. Upon stimulation with forskolin or PI3K inhibitors, latent HSV-1 was efficiently reactivated, leading to renewed viral gene expression and detectable production of infectious particles. These results were reproducible across multiple hiPSC lines, underscoring the scalability and robustness of the system (Oh et al., 2025).

This model represents a significant advance for neurovirology, as it enables direct investigation of neuron-intrinsic mechanisms governing HSV-1 latency and reactivation in a human genetic background. The platform opens new avenues for screening antiviral drugs, studying host-pathogen interactions, and exploring epigenetic regulation of viral genomes.

Comparison with Existing Internal Articles

The present study extends and complements prior internal reviews such as "hiPSC-Derived Sensory Neuron Model for HSV-1 Latency and Reactivation", which provides an overview of the potential of iPSC-derived neuron platforms for HSV-1 research. The key contribution of Oh et al. (2025) lies in rigorous experimental validation and the demonstration of reliable latency and reactivation phenotypes, supported by molecular and functional assays. Furthermore, internal articles like "Strategic Kinase Inhibition in Translational Research: SU..." and "SU 5402: Advanced Receptor Tyrosine Kinase Inhibition for..." discuss the use of multi-kinase inhibitors (such as SU 5402) for dissecting signaling pathways in both cancer biology and neurovirology. While these resources focus on kinase inhibition workflows and translational research strategy, the current paper provides a foundational neuronal model that can be leveraged for such pathway-targeted studies, including apoptosis assay development and cell cycle arrest investigations relevant to both virology and oncology.

Limitations and Transferability

Despite its strengths, the model has certain limitations. The in vitro environment cannot fully recapitulate the complexity of in vivo neuronal networks, immune interactions, or long-term latency dynamics observed in human ganglia. Additionally, while the system supports robust latency and reactivation, it may not capture all molecular nuances of HSV-1 biology in vivo, such as the full spectrum of host immune responses or microenvironmental cues. Transferability to other neurotropic viruses or to high-throughput drug screening workflows will require further optimization and validation.

Research Support Resources

Researchers aiming to interrogate signaling pathways implicated in HSV-1 latency and reactivation can integrate small molecule inhibitors such as SU 5402 (SKU A3843) into their experimental designs. SU 5402 is a potent inhibitor of VEGFR2, FGFR1, and PDGFRβ, and has been widely utilized in cancer biology and multiple myeloma research to study apoptosis and cell cycle arrest. Its established use in modulating kinase-driven pathways, as described in the product information, makes it suitable for pathway dissection in neuronal models of viral infection. For those developing or optimizing apoptosis assays or exploring therapeutic targets in HSV-1-infected neuronal systems, SU 5402 offers a well-characterized tool compound. As always, investigators should ensure compatibility of inhibitor properties (e.g., solubility, storage, and concentration range) with their specific cell models and assay formats.